Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma
Status:
Terminated
Trial end date:
2020-06-30
Target enrollment:
Participant gender:
Summary
This is an open label, phase I/II, dose-escalation study in the initial phase I followed by a
phase II.
The primary objective of the phase I is to determine the maximum tolerated dose (MTD) and
dose limiting toxicity (DLT) of the combinations of TGR-1202 and carfilzomib in participants
with relapsed and refractory (R/R) non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL). The
safety and toxicity of this combination will be evaluated throughout the entire study.
If the combination of TGR-1202 and carfilzomib is found to be feasible and an MTD is
established, the phase II part of the study will be initiated.
Phase II will consist of a 2-stage design of the combination of TGR-1202 and carfilzomib for
participants with R/R NHL.